NCT05761132View on ClinicalTrials.gov

Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2025

Conditions
Vulva CancerVulva NeoplasmSquamous Cell Cancer
Interventions
DRUG

Pembrolizumab

neoadjuvant immunotherapy

Sponsors

Collaborators (1)

Erasmus Medical Center
All Listed Sponsors
collaborator

University Medical Center Groningen

OTHER

collaborator

Erasmus Medical Center

OTHER

lead

Leiden University Medical Center

OTHER